Send to

Choose Destination
Hum Genome Var. 2019 Mar 5;6:12. doi: 10.1038/s41439-019-0044-z. eCollection 2019.

A novel germline mutation of the SFTPA1 gene in familial interstitial pneumonia.

Author information

1Department of Pneumology and Phtiseology, University Hospital and Faculty of Medicine, Brno, Czech Republic.
2Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
3Department of Internal Medicine, Hematology and Oncology, University Hospital and Faculty of Medicine, Brno, Czech Republic.
Contributed equally


Different genes related to alveolar stability have been associated with familial interstitial pneumonia (FIP). Here, we report a novel, rare SFTPA1 variant in a family with idiopathic interstitial pneumonia (IIP). We performed whole-exome sequencing on germline DNA samples from four members of one family; three of them showed signs of pulmonary fibrosis (idiopathic interstitial pneumonia) with autosomal-dominant inheritance. A heterozygous single nucleotide variant c.532 G > A in the SFTPA1 gene has been identified. This variant encodes the substitution p.(Val178Met), localized within the carbohydrate recognition domain of surfactant protein A and segregates with the genes causing idiopathic interstitial pneumonia. This rare variant has not been previously reported. We also analyzed the detected sequence variant in the protein structure in silico. The replacement of valine by the larger methionine inside the protein may cause a disruption in the protein structure. The c.532 G > A variant was further validated using Sanger sequencing of the amplicons, confirming the diagnosis in all symptomatic family members. Moreover, this variant was also found by Sanger sequencing in one other symptomatic family member and one young asymptomatic family member. The autosomal-dominant inheritance, the family history of IIP, and the evidence of a mutation occurring in part of the SFTPA1 gene all suggest a novel variant that causes FIP.

Conflict of interest statement

The authors have received reimbursement from the pharmaceutical industry to cover the costs of participating in several scientific meetings.

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center